In contrast to other mutations affecting key players of epigenetic transcription regulation such as DNMT3A, TET2, or ASXL1, IDH mutations rarely occur as clonal hematopoiesis of indeterminate potential (CHIP), and thus represent an attractive target for AML therapy [51,52]. This evidence concerns the gene IDH1 and acute myeloid leukemia.